A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 2 of 2)
This article was originally published in PharmAsia News
A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.
You may also be interested in...
With U.S. revenues down 29% and the EU take off by 20%, perhaps AstraZeneca’s greatest concern is only 1% revenue growth in emerging markets, which the pharma has targeted as a key revenue-driver through its patent cliff.